Characterization of nonmutagenic Cr(III)-DNA interactions

Sean A. Blankert, Virginia H. Coryell, Brian T. Picard, Kristina K. Wolf, Robert E. Lomas, Diane M Stearns

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Exposure of cells or animals to carcinogenic chromium(VI) (Cr(VI)) produces Cr(III)-DNA adducts. The relevance of these lesions to Cr(VI)-induced tumors is unclear. Various Cr(III) complexes have been used to model the products resulting from Cr(VI) metabolism in order to gain mechanistic insights. The purpose of this study was to characterize interactions of Cr(III) complexes with DNA in order to evaluate their use as models fore these purposes. The reactivity of DNA with chromic chloride hexahydrate (CrCl3) and sodium bis(L-cysteinato)chromium(III) dihydrate (Cr(cys)2-) was compared to that with cis-diamminedichloroplatinum(II) (cis-platin). Both Cr(III) and Pt(II) cause unwinding of supercoiled DNA that can be visualized as a mobility shift by gel electrophoresis. Chromic chloride was much less distorting than cis-platin, unwinding DNA by only 1-2°, and Cr(cys)2- interacted with DNA only weakly. Consistent with in vitro studies, CrCl3 produced Cr-DNA adducts in CHO AA8 cells at levels equivalent to those obtained with Cr(VI), whereas Cr(cys)2- did not produce significant adducts. Lesions produced by CrCl3 were not mutagenic in the hypoxanthine-Gua-phosphoribosyl-transferase assay. These data are consistent with CrCl3 producing a nondistorting lesion, perhaps by association with the phosphate backbone. There are two possible interpretations of these results: Either the Cr(III) products formed by Cr(VI) metabolism are not modeled by CrCl3 and Cr(cys)2- complexes, or Cr(III) is not an active species for Cr(VI)-induced DNA damage. This study provides the first structural evidence for Cr(III)-DNA adducts. A molecular understanding of Cr(III)-DNA interactions will be necessary before we can determine their relevance in Cr(VI)-induced cancers.

Original languageEnglish (US)
Pages (from-to)847-854
Number of pages8
JournalChemical Research in Toxicology
Volume16
Issue number7
StatePublished - Jul 1 2003

Fingerprint

DNA
DNA Adducts
Metabolism
Cisplatin
Superhelical DNA
Hypoxanthine
CHO Cells
Chromium
Transferases
chromium hexavalent ion
Electrophoresis
DNA Damage
Tumors
Assays
Neoplasms
Animals
Gels
Sodium
Phosphates
Association reactions

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Blankert, S. A., Coryell, V. H., Picard, B. T., Wolf, K. K., Lomas, R. E., & Stearns, D. M. (2003). Characterization of nonmutagenic Cr(III)-DNA interactions. Chemical Research in Toxicology, 16(7), 847-854.

Characterization of nonmutagenic Cr(III)-DNA interactions. / Blankert, Sean A.; Coryell, Virginia H.; Picard, Brian T.; Wolf, Kristina K.; Lomas, Robert E.; Stearns, Diane M.

In: Chemical Research in Toxicology, Vol. 16, No. 7, 01.07.2003, p. 847-854.

Research output: Contribution to journalArticle

Blankert, SA, Coryell, VH, Picard, BT, Wolf, KK, Lomas, RE & Stearns, DM 2003, 'Characterization of nonmutagenic Cr(III)-DNA interactions', Chemical Research in Toxicology, vol. 16, no. 7, pp. 847-854.
Blankert SA, Coryell VH, Picard BT, Wolf KK, Lomas RE, Stearns DM. Characterization of nonmutagenic Cr(III)-DNA interactions. Chemical Research in Toxicology. 2003 Jul 1;16(7):847-854.
Blankert, Sean A. ; Coryell, Virginia H. ; Picard, Brian T. ; Wolf, Kristina K. ; Lomas, Robert E. ; Stearns, Diane M. / Characterization of nonmutagenic Cr(III)-DNA interactions. In: Chemical Research in Toxicology. 2003 ; Vol. 16, No. 7. pp. 847-854.
@article{72e40b490dab463eaa49d45e28372dbc,
title = "Characterization of nonmutagenic Cr(III)-DNA interactions",
abstract = "Exposure of cells or animals to carcinogenic chromium(VI) (Cr(VI)) produces Cr(III)-DNA adducts. The relevance of these lesions to Cr(VI)-induced tumors is unclear. Various Cr(III) complexes have been used to model the products resulting from Cr(VI) metabolism in order to gain mechanistic insights. The purpose of this study was to characterize interactions of Cr(III) complexes with DNA in order to evaluate their use as models fore these purposes. The reactivity of DNA with chromic chloride hexahydrate (CrCl3) and sodium bis(L-cysteinato)chromium(III) dihydrate (Cr(cys)2-) was compared to that with cis-diamminedichloroplatinum(II) (cis-platin). Both Cr(III) and Pt(II) cause unwinding of supercoiled DNA that can be visualized as a mobility shift by gel electrophoresis. Chromic chloride was much less distorting than cis-platin, unwinding DNA by only 1-2°, and Cr(cys)2- interacted with DNA only weakly. Consistent with in vitro studies, CrCl3 produced Cr-DNA adducts in CHO AA8 cells at levels equivalent to those obtained with Cr(VI), whereas Cr(cys)2- did not produce significant adducts. Lesions produced by CrCl3 were not mutagenic in the hypoxanthine-Gua-phosphoribosyl-transferase assay. These data are consistent with CrCl3 producing a nondistorting lesion, perhaps by association with the phosphate backbone. There are two possible interpretations of these results: Either the Cr(III) products formed by Cr(VI) metabolism are not modeled by CrCl3 and Cr(cys)2- complexes, or Cr(III) is not an active species for Cr(VI)-induced DNA damage. This study provides the first structural evidence for Cr(III)-DNA adducts. A molecular understanding of Cr(III)-DNA interactions will be necessary before we can determine their relevance in Cr(VI)-induced cancers.",
author = "Blankert, {Sean A.} and Coryell, {Virginia H.} and Picard, {Brian T.} and Wolf, {Kristina K.} and Lomas, {Robert E.} and Stearns, {Diane M}",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "16",
pages = "847--854",
journal = "Chemical Research in Toxicology",
issn = "0893-228X",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Characterization of nonmutagenic Cr(III)-DNA interactions

AU - Blankert, Sean A.

AU - Coryell, Virginia H.

AU - Picard, Brian T.

AU - Wolf, Kristina K.

AU - Lomas, Robert E.

AU - Stearns, Diane M

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Exposure of cells or animals to carcinogenic chromium(VI) (Cr(VI)) produces Cr(III)-DNA adducts. The relevance of these lesions to Cr(VI)-induced tumors is unclear. Various Cr(III) complexes have been used to model the products resulting from Cr(VI) metabolism in order to gain mechanistic insights. The purpose of this study was to characterize interactions of Cr(III) complexes with DNA in order to evaluate their use as models fore these purposes. The reactivity of DNA with chromic chloride hexahydrate (CrCl3) and sodium bis(L-cysteinato)chromium(III) dihydrate (Cr(cys)2-) was compared to that with cis-diamminedichloroplatinum(II) (cis-platin). Both Cr(III) and Pt(II) cause unwinding of supercoiled DNA that can be visualized as a mobility shift by gel electrophoresis. Chromic chloride was much less distorting than cis-platin, unwinding DNA by only 1-2°, and Cr(cys)2- interacted with DNA only weakly. Consistent with in vitro studies, CrCl3 produced Cr-DNA adducts in CHO AA8 cells at levels equivalent to those obtained with Cr(VI), whereas Cr(cys)2- did not produce significant adducts. Lesions produced by CrCl3 were not mutagenic in the hypoxanthine-Gua-phosphoribosyl-transferase assay. These data are consistent with CrCl3 producing a nondistorting lesion, perhaps by association with the phosphate backbone. There are two possible interpretations of these results: Either the Cr(III) products formed by Cr(VI) metabolism are not modeled by CrCl3 and Cr(cys)2- complexes, or Cr(III) is not an active species for Cr(VI)-induced DNA damage. This study provides the first structural evidence for Cr(III)-DNA adducts. A molecular understanding of Cr(III)-DNA interactions will be necessary before we can determine their relevance in Cr(VI)-induced cancers.

AB - Exposure of cells or animals to carcinogenic chromium(VI) (Cr(VI)) produces Cr(III)-DNA adducts. The relevance of these lesions to Cr(VI)-induced tumors is unclear. Various Cr(III) complexes have been used to model the products resulting from Cr(VI) metabolism in order to gain mechanistic insights. The purpose of this study was to characterize interactions of Cr(III) complexes with DNA in order to evaluate their use as models fore these purposes. The reactivity of DNA with chromic chloride hexahydrate (CrCl3) and sodium bis(L-cysteinato)chromium(III) dihydrate (Cr(cys)2-) was compared to that with cis-diamminedichloroplatinum(II) (cis-platin). Both Cr(III) and Pt(II) cause unwinding of supercoiled DNA that can be visualized as a mobility shift by gel electrophoresis. Chromic chloride was much less distorting than cis-platin, unwinding DNA by only 1-2°, and Cr(cys)2- interacted with DNA only weakly. Consistent with in vitro studies, CrCl3 produced Cr-DNA adducts in CHO AA8 cells at levels equivalent to those obtained with Cr(VI), whereas Cr(cys)2- did not produce significant adducts. Lesions produced by CrCl3 were not mutagenic in the hypoxanthine-Gua-phosphoribosyl-transferase assay. These data are consistent with CrCl3 producing a nondistorting lesion, perhaps by association with the phosphate backbone. There are two possible interpretations of these results: Either the Cr(III) products formed by Cr(VI) metabolism are not modeled by CrCl3 and Cr(cys)2- complexes, or Cr(III) is not an active species for Cr(VI)-induced DNA damage. This study provides the first structural evidence for Cr(III)-DNA adducts. A molecular understanding of Cr(III)-DNA interactions will be necessary before we can determine their relevance in Cr(VI)-induced cancers.

UR - http://www.scopus.com/inward/record.url?scp=0042809632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042809632&partnerID=8YFLogxK

M3 - Article

C2 - 12870887

AN - SCOPUS:0042809632

VL - 16

SP - 847

EP - 854

JO - Chemical Research in Toxicology

JF - Chemical Research in Toxicology

SN - 0893-228X

IS - 7

ER -